Migraine in Women Not Linked to Risk for Parkinson Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- Migraine is not associated with an increased risk for developing Parkinson disease (PD) among women, according to a study published online Aug. 21 in Neurology.
Ricarda S. Schulz, from Charité-Universitätsmedizin Berlin, and colleagues used data from the Women's Health Study involving women aged 45 years and older at baseline (1992 to 1995) to estimate the effect of migraine, migraine subtypes, and migraine episode frequency on the risk for developing PD. A total of 39,312 women were included in the analyses and were followed for self-reported physician-diagnosed PD through Dec. 31, 2021.
The researchers found that 18.6 percent of the women reported any migraine at baseline, and of these women, 5.5, 5.2, and 7.9 percent reported a history of migraine, migraine with aura, and migraine without aura, respectively. A total of 685 PD cases were reported during a mean follow-up of 22.0 years. Of these, 18.7 and 81.3 percent were reported by women who also reported any migraine and those without migraine, respectively. The hazard ratio for the association of any migraine on the risk for PD was not significant after adjusting for confounders (hazard ratio, 1.07; 95 percent confidence interval, 0.88 to 1.29). Furthermore, no significant associations were seen for migraine with aura, migraine without aura, or history of migraine (hazard ratios [95 percent confidence intervals], 0.87 [0.59 to 1.27], 1.21 [0.93 to 1.58], and 1.05 [0.76 to 1.45], respectively).
"In this large prospective study of women in health professions in the United States aged at least 45 years at baseline, we found no association between migraine, migraine aura status, or migraine frequency on the risk of PD," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Review Compares Drug Interventions for Acute Migraine Treatment
MONDAY, Sept. 23, 2024 -- All active interventions show superior efficacy to placebo for freedom from pain, and most do for sustained pain freedom, for the acute treatment of...
Air Pollution Exposure Increases Risk for Parkinson Disease
FRIDAY, Sept. 20, 2024 -- Higher exposure to air pollution increases the risk for Parkinson disease (PD), according to a study published online Sept. 16 in JAMA Network...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
WEDNESDAY, Sept. 18, 2024 -- For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.